CKD in Iran Presented by: SM Gatmiri, MD, Nephrologist Imam Khomeini Hospital, TUMSNRC In The Name...
Preview:
Citation preview
- Slide 1
- CKD in Iran Presented by: SM Gatmiri, MD, Nephrologist Imam
Khomeini Hospital, TUMSNRC In The Name of God
- Slide 2
- CKD -A worldwide problem. -Rising incidence &
prevalence.
- Slide 3
- CKD Definition 1 -Kidney damage 3months, -Structural
(pathological) or -Functional (composition of blood or urine) or
-Imaging abnormalities -With or without decreased GFR. OR
- Slide 4
- CKD Definition 2 -Presence of GFR
- Slide 5
- Stage 1: NL GFR (>90 mL/min/1.73 m2) & persistent
albuminuria (1.8% of the total US adult population). Stage 2: GFR
60 to 89 mL/min/1.73 m2 & persistent albuminuria (3.2%). Stage
3: GFR 30 & 59 mL/min/1.73 m2 (7.7%). Stage 4: GFR 15 & 29
mL/min/1.73 m2 (0.35%). Stage 5: GFR of
- Slide 6
- The number of ESRD in US has increased from -10,000 in 1973 to
-86,354 in 1983, & to -527,283 as of December 31, 2007.
- Slide 7
- In 2007 alone, 111,000 patients entered the US ESRD program.
(Incidence: 440 PMP)
- Slide 8
- Patients with ESRD consume a disproportionate share of health
care resources.
- Slide 9
- Total Medicare DM CHF Dialysis/Tx CKD Numbers 5.8% 1.1%
20.7%25.1% 41.3%48.1% 19% 7.8% CKD, CHF & DM; Number of
patients & costs; USA 2002 Costs Collins AJ; USRDS
database
- Slide 10
- The total cost of the ESRD program in the US was approximately
$35.32 billion in 2007.
- Slide 11
- However CKD in the US, is under- diagnosed &
under-treated.
- Slide 12
- Iran Area: 1.648 million Sq Km Population : 68,017,860 Median
Age : 24.23,Life Expectancy : 69.96 Total Health Expenditure of GDP
: 6%
- Slide 13
- ESRD in Iran 12% Prevalence : 357 PMP Incidence :66 PMP CKD
epidemiology in Iran Mitra Mahdavi-Mazdeh- Assessment of HD
patients , Iran ;NDT (2007)
- Slide 14
- Mean age difference in ESRD patients during last 10 years in
Iran
- Slide 15
- Sex difference in ESRD patients during last 10 years
- Slide 16
- Causes of ESRD in the last 10 years in Iran
- Slide 17
- Sex difference in ESRD patients during last 10 years in Iran
male to female ratio is 1.33.
- Slide 18
- Diabetes as the cause of ESRD in the last 10years
- Slide 19
- HTN & DM as the causes of ESRD in the last 10 years in
Iran
- Slide 20
- The number Of ESRD will be doubled in next 10 years
- Slide 21
- Annual RRT Cost with total health expenditure of GDP of 6%
-Dialysis sessions: 800Billion R for 13000 Pts (>60,000,000
R/Pts) -R Tx drugs =500 B R -for 12000 Pts (>40,000,000
R/Pts)
- Slide 22
- RRT program so far? Kidney Transplant CAPD HD centers
- Slide 23
- Time to change our approach: decrease ESRD number or its
postponing
- Slide 24
- Mahdavi-Mazdeh :IJKD.vol:4,no:4, 2010 Population-Based
Screening CKD in Iran:
- Slide 25
- What is Solution? We Should push for a CKD education To take
serious high NL Cr To take serious HTN &Diabetes management CKD
should be viewed as the third part of the deadly triangle with DM
and CVD affecting the health & welfare of the general
population
- Slide 26
- What is Our Common Task As -Nephrologists -Internist -GPs
-Health Authorities?
- Slide 27
- Education 1. Primordial Prevention : Healthy Diet, Changes in
Social, Cultural and Personal Habits 2. Early Detection, Referral
and Control of HTN & DM Public Education Professional (Health
Care Personnel) Education
- Slide 28
- CKD Patients receiving ACE-Is/ARBs NHANES III 19881994 &
NHANES 19992002 patients age 60 & older; patients with eGFRs of
less than 15 ml/min/1.73 m 2 are excluded. *Sample size less than
30, or coefficient of variation is not less than 30 percent.
- Slide 29
- Vascular Access: New Medical Evidence Form 2728 Data, May
2005-Dec 2006 82% of patients are using a catheter as their first
outpatient access!!!! Only 13% of incident HD patients used a
fistula as their first access. Assessment of HD patients , Iran
;NDT (2007)
- Slide 30
- AVF use in Canadian prevalent (53%) and incident (26%)patients.
In Europe [prevalent(74%), incident(50%) AVF is the advocated
access route in Iran [prevalent (91%), incident(37.5%)in Tehran].
Assessment of HD patients , Iran ;NDT (2007) Vascular Access
- Slide 31
- Message: -CKD & ESRD is increased & highly prevalent -A
strong CVD risk factor.
- Slide 32
- Message -We can detect CKD with simple tests & there are
treatments for CKD.
- Slide 33
- Message: -ESRD is increasing, more than increases in number of
HD facility & Tx.
- Slide 34
- Message -We should consider CKD prevention & place initial
focus on strategies that slow disease progression to postpone
RRT.
- Slide 35